Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.42 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.40 |
| ▸ | FEN1 | P39748 | 1/20 | 0.40 |
| ▸ | GPBAR1 | Q8TDU6 | 13/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | LIPE | Q05469 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4494251 | 0.91 | MEN1 (0.48) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL4494482 | 0.89 | MEN1 (0.42) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL4509473 | 0.89 | KMT2A (0.57) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL5236265 | 0.88 | KMT2A (0.56) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL4496687 | 0.88 | KMT2A (0.56) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL4510344 | 0.88 | KMT2A (0.56) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL4506552 | 0.88 | KMT2A (0.56) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL4507747 | 0.88 | KMT2A (0.56) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL4509930 | 0.87 | HDAC4 (0.47) | MEN1KMT2APGRHDAC4ERCC5 | |
| SCHEMBL5233610 | 0.87 | MEN1 (0.42) | MEN1KMT2APGRHDAC4GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553849-B2 | Compounds | ACTIVE BIOTECH AB (SE) | 2009-06-30 | — | — | US | claimed |
| EP-1776369-B1 | THIENOPYRIDONE CARBOXAMIDES AND THEIR MEDICAL USE | ACTIVE BIOTECH AB (SE) | 2007-10-10 | — | — | EP | claimed |
| US-20060004038-A1 | Novel compounds | ACTIVE BIOTECH AB (SE) | 2006-01-05 | — | — | US | claimed |
| US-7553849-B2 | Compounds | ACTIVE BIOTECH AB (SE) | 2009-06-30 | — | — | US | disclosed |
| EP-1776369-B1 | THIENOPYRIDONE CARBOXAMIDES AND THEIR MEDICAL USE | ACTIVE BIOTECH AB (SE) | 2007-10-10 | — | — | EP | disclosed |
| US-20060004038-A1 | Novel compounds | ACTIVE BIOTECH AB (SE) | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060004038-A1 | Novel compounds | REL, CLIC4, C5 | MEN1 509/4885KMT2A 4071/4885PGR 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.